Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EPS (Weighted Average and Diluted): 2015-2024

Historic EPS (Weighted Average and Diluted) for Summit Therapeutics (SMMT) over the last 9 years, with Dec 2024 value amounting to -$0.31.

  • Summit Therapeutics' EPS (Weighted Average and Diluted) fell 287.50% to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.25, marking a year-over-year decrease of 420.83%. This contributed to the annual value of -$0.31 for FY2024, which is 68.69% up from last year.
  • Latest data reveals that Summit Therapeutics reported EPS (Weighted Average and Diluted) of -$0.31 as of FY2024, which was up 68.69% from -$0.99 recorded in FY2023.
  • In the past 5 years, Summit Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.31 during FY2024, and its lowest value of -$0.99 during FY2023.
  • For the 3-year period, Summit Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.57, with its median value being -$0.41 (2022).
  • As far as peak fluctuations go, Summit Therapeutics' EPS (Weighted Average and Diluted) plummeted by 141.46% in 2023, and later surged by 68.69% in 2024.
  • Yearly analysis of 5 years shows Summit Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.76 in 2020, then climbed by 11.84% to -$0.67 in 2021, then surged by 38.81% to -$0.41 in 2022, then tumbled by 141.46% to -$0.99 in 2023, then soared by 68.69% to -$0.31 in 2024.